Nasdaq Panel Upholds Delisting of Platinum Analytics Securities
Trading was suspended after the panel cited potential manipulation concerns and insufficient liquidity, while the company plans to seek a review.

Every Stocks story we have published, newest first.
58 stories in the last 24 hours
Updated 7:16 PM (Times shown in New York time (ET))
Page 13 of 26 · 604 stories
Trading was suspended after the panel cited potential manipulation concerns and insufficient liquidity, while the company plans to seek a review.

He sees a coming memory-chip glut and says five companies outside AI have fallen to attractive prices.

The publisher points to flat margins and modest returns on invested capital, while shares recently traded below their six-month-ago level.

The publisher pointed to slower five-year revenue growth and falling per-share earnings, while noting a recent rise in tangible book value.

StockStory cited five-year revenue growth, gross margins and cash generation despite a six-month decline in Matador shares.

StockStory cited slower unit growth and declining returns, despite Champion Homes shares rising over the past six months.

StockStory cited slower five-year sales and earnings growth and falling returns, despite a 29.3% share gain over six months.

StockStory’s analysts point to flat premiums, muted revenue expectations and slow EPS growth as reasons for caution on Enact.

Chairman Rolf Gerritsen says Tomahawk is preparing an AIM move, with Slovakian technical work and Australian gold sampling shaping the timetable.

A sharp rally in AI-linked shares lifted the Nasdaq to a record, while an investor strategist argued the AI trade still has room to grow.

Johnson & Johnson shares climbed despite slower revenue growth, as investors weigh new-drug momentum against Stelara losses and softer MedTech sales.

The franchisor says Meritage lost its operating rights over unpaid fees, setting up a fight over who will run the restaurants.

As Warren Buffett leaves the chairmanship, his decades-old advice on market fear and investor patience remains central to Berkshire’s handoff.

The Canadian producer will sell flower through GROW Group under Spectrum Therapeutics, extending its European medical cannabis business.

The $15 target reflects caution about AI infrastructure financing and construction risks, despite rising data-center lease revenue at TeraWulf.

The Australian graphene maker will issue 6.47 million shares, with proceeds aimed at expanding production and advancing battery development.

A 24/7 Wall St. model sees roughly 50% upside, but Oracle’s heavy data-center spending leaves investors watching cash flow and delivery.

Options pricing points to a wide one-year range, while slowing growth and cyberattack-related losses complicate Boston Scientific’s rebound case.

The bank’s Sell rating challenges the AI cloud provider’s growth story, pointing to credit risks and pressure on future infrastructure spending.

The Trump-Xi summit puts renewed attention on crop exports, but existing purchase pledges have yet to translate fully into trade.

Quarterly sales barely changed, while higher spending and a widening adjusted loss put pressure on D-Wave to turn orders into revenue.

Investors are paying far less for Nvidia’s forecast earnings, even as sales and profits surge and the company projects more growth.

The U.S. spirits maker is targeting a European foothold with a cash bid carrying a 68% premium and plans to delist Berentzen.

CFG has beaten the financial-sector ETF over longer periods, though its recent pullback and weaker three-month showing complicate the picture.
